From Lithium Biomining to Cell-Cultured Chocolate: Inside BioMADE's $21.4 Million Biomanufacturing Bet

A startup in the lithium extraction business probably doesn't expect to share a funding announcement with a team engineering cell-cultured chocolate. But that's exactly what happened on April 29, when BioMADE — the Department of Defense's Manufacturing Innovation Institute for bioindustrial manufacturing — unveiled $21.4 million across 14 projects that span the full width of what biology-as-manufacturing-platform can do.

The projects are striking in their range. AlkaLi Labs is developing microbial processes to pull lithium from oil and gas production wastewater. UC Davis and California Cultured are growing cacao plant cells in bioreactors to produce chocolate without farms. Boston University and Capra Biosciences are building wireless sensors that live inside fermentation vessels, feeding real-time data to AI systems that optimize yields. MIT is designing a national biomanufacturing curriculum.

What ties them together is a funding model that didn't exist before this announcement: a first-ever partnership between the Department of Defense and the National Science Foundation that creates a single pipeline from basic research through production-scale manufacturing.

The Pipeline Problem BioMADE Is Solving

Biomanufacturing has a transition gap that mirrors — and in some ways exceeds — the "valley of death" in traditional defense technology. A university researcher demonstrates that engineered microbes can produce a valuable compound in a flask. The science is published. The grant ends. And the compound never reaches a bioreactor, because the engineering challenges between bench-scale demonstration and pilot-scale production are nobody's funded responsibility.

NSF funds basic research — Manufacturing Readiness Levels 1 through 3, where you prove something is scientifically possible. DoD manufacturing programs fund MRL 4 through 7, where you prove something can be made reliably and at scale. The space between MRL 3 and MRL 4 is where biomanufacturing innovations go to die.

The new NSF-BioMADE partnership explicitly bridges this gap. NSF funds the basic research components of each integrated project — the proof-of-concept work, the strain engineering, the fundamental biology. BioMADE picks up the same project and funds the technology maturation, risk reduction, and scale-up. One project, two funding sources, no gap.

Seven NSF programs are participating: Systems and Synthetic Biology, BioSensing, Cellular Engineering, Disability Engineering, Environmental Sustainability, Nanoscale Interactions, and Process Systems. Critically, the NSF-funded portion requires no BioMADE membership and no cost-sharing — the standard NSF rules apply. The BioMADE portion follows the institute's membership and cost-share requirements, which brings industry partners to the table with skin in the game.

What the $21.4 Million Is Actually Buying

The 14 projects break into three categories, and the funding split reveals DoD's priorities.

Technology and innovation projects received $4.6 million from DoD and $2.2 million from NSF, with $4.8 million in industry cost-share — six projects totaling $11.6 million. These are the headline makers:

AlkaLi Labs is engineering microorganisms to extract lithium from produced water — the briny wastewater that comes up during oil and gas drilling. The U.S. produces billions of barrels of this water annually, and much of it contains lithium concentrations that are economically interesting but too low for conventional extraction. Biological extraction could turn a waste disposal problem into a domestic supply of the most critical battery material on the planet. For a Department of Defense increasingly worried about Chinese dominance of lithium processing, this project is strategically obvious.

Mango Materials and UC Davis are tackling polyhydroxyalkanoates — biodegradable plastics produced by bacteria that consume methane. PHAs can replace petroleum-based plastics in films, fibers, and 3D printing, but production costs remain too high for commercial viability. This project targets the downstream processing bottleneck, where separating the polymer from the bacterial biomass eats most of the margin.

Triplebar and UC Berkeley are using genomic language models — the biological equivalent of large language models — to optimize microbial strains for producing proteins used in wound healing and chemical defense. The AI angle here is significant: rather than testing thousands of genetic variants in the lab, the models predict which modifications will improve protein yield before a single experiment runs.

Boston University and Capra Biosciences are developing in-fermenter microbial-electronic sensors — wireless devices that sit inside bioreactors and generate real-time data streams. Paired with AI and machine learning, these sensors enable predictive process control that could dramatically improve yields and reduce batch failures. Anyone who has watched a $50,000 fermentation run crash because a pH drift went undetected for two hours understands why this matters.

Roke Biotechnologies and Duke University are engineering nanobody-based replacements for expensive growth factors used in cell culture. Growth factors are often the single largest cost in producing biological therapeutics and diagnostics. Cheaper alternatives unlock distributed manufacturing — producing critical medical countermeasures at the point of need rather than shipping them from centralized facilities.

And then there's the chocolate. UC Davis and California Cultured are using plant cell culture to produce cacao — the raw material for chocolate — without land, without tropical deforestation, without the child labor problems that plague West African cacao farming. The defense relevance is less obvious here, but the underlying plant cell culture technology has applications in producing any high-value botanical compound, including some with pharmaceutical and defense applications.

Workforce Projects That Actually Connect to Jobs

Six projects totaling $9.6 million ($4.4 million DoD, $5.2 million cost-share) focus on workforce development — and unlike many federal workforce programs, these are designed with specific employer commitments attached.

MIT's "How To Grow (Almost) Anything" program is building a national curriculum network for biomanufacturing education, with lab modules and real-world project components. The MIT brand matters here: community colleges and state universities that adopt this curriculum can credibly claim alignment with cutting-edge research.

Manus Bio and the University of Georgia are creating an apprenticeship framework specifically for pilot-scale bioreactor operators — the technicians who actually run the equipment that turns lab-scale successes into commercial products. This role barely exists in formal workforce training programs today, which is one reason biomanufacturing companies consistently report that hiring is their biggest bottleneck.

Dakota BioWorx and South Dakota Biotech are launching a training program with an explicit veteran workforce transition component. South Dakota might seem like an unlikely biomanufacturing hub, but the state's agricultural biotechnology sector creates natural feedstock advantages, and its military installations produce a steady flow of separating service members with technical backgrounds.

UC Davis, MiraCosta College, and Modesto Junior College are running SPRINT — Scalable Protein Research Training — designed to prepare thousands of community college students for biomanufacturing careers. The community college pipeline is arguably the most important workforce channel for the sector, because biomanufacturing technician roles typically require associate degrees or certificates, not four-year degrees.

UNCG is developing a BioMISSION undergraduate certificate with industry capstones and data analytics integration, and Biocom Institute is running a Life Science Career Fellowship connecting community college students in Los Angeles and the Bay Area with industry mentorship.

How to Get Into the Next Round

BioMADE operates on a project call model — periodic solicitations open to its 300-plus member organizations across 40 states. Membership is the gateway, and it's more accessible than most people assume. Academic institutions, small businesses, and nonprofits can join, and the membership tiers include options scaled to organization size.

For NSF-funded researchers, the pathway is now direct. If your work falls within the seven participating NSF programs — Systems and Synthetic Biology, BioSensing, Cellular Engineering, Disability Engineering, Environmental Sustainability, Nanoscale Interactions, or Process Systems — you can submit integrated proposals that span NSF and BioMADE funding simultaneously. The NSF portion follows standard NSF rules with no membership or cost-share requirement. You submit through BioMADE's project call process with a simultaneous NSF submission, starting with a white paper.

This dual-submission model is genuinely new. Historically, researchers had to choose between basic science funding (NSF, NIH) and translational manufacturing funding (DoD Manufacturing Innovation Institutes, DOE). The integrated approach means you don't have to finish your basic research grant, publish, and then separately apply for manufacturing support years later. You design the full pipeline from the start.

For small businesses, BioMADE's cost-share requirements are the key constraint. The technology projects in this round carried significant industry matching — $4.8 million against $6.8 million in federal funding. Companies need to demonstrate that they can bring private capital or in-kind contributions to the table. But the matching also signals something important: DoD is funding projects where industry has already decided the technology is commercially viable enough to co-invest.

The National Security Angle Nobody Is Talking About

BioMADE CEO Douglas Friedman framed the announcement around a "critical tipping point" in global bioindustrial manufacturing competition. He's not being hyperbolic. China's national biomanufacturing strategy has committed tens of billions of dollars to building fermentation capacity, synthetic biology infrastructure, and bio-based chemical production. The European Union's bioeconomy initiative is similarly ambitious.

The United States still leads in basic bioscience research — but translating that research into domestic manufacturing capability is where the gap keeps widening. Every project in this BioMADE round addresses some dimension of that gap: domestic lithium supply, onshore polymer production, AI-driven manufacturing optimization, workforce pipelines that don't yet exist at scale.

The two safety and security projects — small at $262,000 combined — hint at another dimension. Boundless Impact Research and Analytics is developing life cycle analysis frameworks for biopesticides, and Checkerspot is building resilience assessments for domestic feedstocks. These aren't glamorous, but they're the kind of foundational risk analysis that determines whether biomanufacturing supply chains can actually withstand disruption.

For grant seekers watching the biomanufacturing space, the signal is clear: the DoD-NSF partnership model is likely to expand. Both agencies have been moving toward integrated funding for years, and BioMADE's 14-project pilot gives them a proof point. Researchers working at the intersection of biology, manufacturing, and AI should be watching BioMADE's project calls for the next solicitation — and using tools like Granted to identify complementary federal funding opportunities that strengthen their integrated proposals.